Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Watch
Expert ConversationsShows & PodcastNews & Analysis
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Charles E. Geyer, MD, FACP

Advertisement

Articles by Charles E. Geyer, MD, FACP

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

ByCharles E. Geyer, MD, FACP
March 28th 2022

Charles E. Geyer, MD, FACP, discusses dosing strategies and adverse event management with olaparib.

Advertisement

Latest Updated Articles

  • Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer
    Dr. Geyer Highlights Optimal Dosing Strategies for New Olaparib Indication in Breast Cancer

    March 28th 2022



Advertisement
Advertisement

Trending on Oncology Nursing News

1

Patient Safety First: How a CNS Bridges Oncology Research and the Bedside

2

FDA Grants Accelerated Approval to Dostarlimab in dMMR Rectal Cancer

3

Anktiva Plus BCG: 84% of Responders Cystectomy-Free at 3 Years

4

Making Innovation Meaningful: Enabling Personalized Care in Multiple Myeloma

5

Tucatinib Maintenance for HER2+ Breast Cancer: What Nurses, PAs Should Know

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us